Tango Therapeutics Inc
$ 24.06
11.60%
14 Apr - close price
- Market Cap 3,433,094,000 USD
- Current Price $ 24.06
- High / Low $ 24.08 / 21.58
- Stock P/E N/A
- Book Value 2.55
- EPS -0.87
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.37 %
- 52 Week High 24.08
- 52 Week Low 1.03
About
Tango Therapeutics Inc. is a clinical-stage biotechnology firm focused on revolutionizing cancer treatment through targeted therapies based on the principle of synthetic lethality. With a robust and diverse pipeline of innovative drug candidates, the company is poised to make significant strides in precision oncology. Tango is committed to enhancing its research capabilities through strategic partnerships with esteemed academic institutions, further solidifying its role as a leader in advancing treatment paradigms in oncology. Through its visionary approach, Tango aims to address critical unmet needs in cancer care and significantly improve patient outcomes.
Analyst Target Price
$21.40
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNGX
2026-04-16 09:08:43
Tango Therapeutics has announced key leadership appointments to accelerate the late-stage development of vopimetostat, a PRMT5 inhibitor for pancreatic cancer. Matthew Gall was appointed Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD, as SVP, Corporate Strategy and Project Leadership. These appointments aim to strengthen Tango’s leadership as it progresses vopimetostat towards potential regulatory approval and prepares for commercialization.
2026-04-15 13:39:13
Tango Therapeutics has bolstered its leadership team by appointing Matthew Gall as Chief Financial Officer and bringing in Yen-Ching Chua as Chief Development Operations Officer and Janice Kapty as Senior Vice President of Corporate Strategy. These strategic hires aim to support the company as it prepares to advance its lead cancer drug, vopimetostat, into late-stage development and build capabilities for eventual commercialization. The moves reflect the company's transition into a more mature development phase, focusing on operational execution and financial planning for regulatory approval and commercial success.
2026-04-15 13:39:13
Tango Therapeutics has announced key leadership appointments to support the late-stage development and potential commercialization of vopimetostat, a PRMT5 inhibitor for pancreatic and other cancers. Matthew Gall has been appointed Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD as SVP, Corporate Strategy and Project Leadership. These appointments aim to strengthen the company's capabilities as it prepares to present crucial clinical data this year.
2026-04-15 13:39:13
Tango Therapeutics (TNGX) announced a significant leadership reshuffle, appointing Matthew Gall as the new CFO and Jessica Newcomb as principal accounting officer, effective April 15, 2026. These changes, alongside new hires in development operations and corporate strategy, are aimed at strengthening the company's financial and operational capabilities as it advances its lead drug candidate, vopimetostat, into late-stage clinical trials for pancreatic cancer and prepares for potential commercialization. Despite strong technical momentum, TipRanks' AI Analyst, Spark, rates TNGX as Neutral due to weak financial performance and ongoing unprofitability.
2026-04-15 13:39:13
Tango Therapeutics (NASDAQ: TNGX) has appointed Matthew Gall as its new Chief Financial Officer, succeeding Daniella Beckman. The clinical-stage biotech also announced two other leadership appointments: Yen-Ching Chua as Chief Development Operations Officer and Janice Kapty as SVP, Corporate Strategy and Project Leadership. These appointments aim to support the development and potential regulatory approval of vopimetostat, the company's PRMT5 inhibitor for pancreatic cancer.
2026-04-15 13:39:13
Tango Therapeutics announced significant leadership changes to support its late-stage oncology pipeline, including the appointment of Matthew Gall as the new Chief Financial Officer and principal financial officer, replacing Daniella Beckman. Jessica Newcomb has been named principal accounting officer, and additional senior leaders in development operations and corporate strategy have been hired to advance vopimetostat towards regulatory approval. These strategic hires aim to align financial, operational, and strategic leadership with the company's goals for late-stage development and potential commercialization.
